Cell Therapy Quality Control Market
完整報告名稱與涵蓋範圍
Cell Therapy Quality Control Market Size, Share & Trends Analysis Report, By Test Type (Sterility, Mycoplasma and Endotoxin Testing, Identity, Purity and Potency Assays, Vector Copy Number and Genomic Integrity Testing, Cell Counting, Viability and Phenotyping), By Product Type (Instruments and Analyzers, Reagents, Kits and Consumables, Software and Data Management, Contract Testing Services), By Technology (Flow Cytometry, PCR and Sequencing-Based Methods, Rapid Microbiological Methods, Cell-Based Potency and Functional Assays), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The cell therapy quality control market covers instruments, reagents, software and contract testing services used to characterise and release cell-based therapies, including sterility, mycoplasma and endotoxin testing, identity, purity and potency assays, vector copy number and genomic integrity testing, and cell counting, viability and phenotyping. Quality control for conventional biologics and viral vector manufacturing analytics are addressed separately and excluded here.
Testing is a disproportionate cost and time driver in cell therapy because each autologous batch must be released individually, often within days, from small sample volumes. Developers and manufacturers are adopting rapid microbiological methods that cut sterility results from two weeks to days, automated flow cytometry and digital PCR for identity and vector copy number, cell-based and reporter potency assays that regulators increasingly require before pivotal trials, and software that automates data review and electronic batch records. Regulatory guidance on potency assurance and comparability, plus the shift to allogeneic and point-of-care manufacturing, is expanding the assay portfolio and driving demand for validated, platform-based methods.
North America and Europe dominate spending, with China, Japan and South Korea expanding as domestic products reach commercialisation. Competition involves life science tool providers, contract testing laboratories and specialised advanced therapy analytics companies.
The InsightAce study delivers revenue forecasts in US$ across all test type, product type, technology and end user and regional segments for 2026-2035, alongside segment-level trend analysis, competitive landscape assessment and detailed company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cell Therapy Quality Control Market Snapshot
Chapter 4. Global Cell Therapy Quality Control Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Test Type Estimates & Trend Analysis
5.1. Test Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Test Type:
5.2.1. Sterility, Mycoplasma and Endotoxin Testing
5.2.2. Identity, Purity and Potency Assays
5.2.3. Vector Copy Number and Genomic Integrity Testing
5.2.4. Cell Counting, Viability and Phenotyping
Chapter 6. Market Segmentation 2: By Product Type Estimates & Trend Analysis
6.1. Product Type & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Product Type:
6.2.1. Instruments and Analyzers
6.2.2. Reagents, Kits and Consumables
6.2.3. Software and Data Management
6.2.4. Contract Testing Services
Chapter 7. Market Segmentation 3: By Technology Estimates & Trend Analysis
7.1. Technology & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Technology:
7.2.1. Flow Cytometry
7.2.2. PCR and Sequencing-Based Methods
7.2.3. Rapid Microbiological Methods
7.2.4. Cell-Based Potency and Functional Assays
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Cell Therapy Developers
8.2.2. CDMOs
8.2.3. Academic and Hospital Manufacturing Facilities
Chapter 9. Cell Therapy Quality Control Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Charles River Laboratories International, Inc.
11.2. Eurofins Scientific SE
11.3. Sartorius AG
11.4. Thermo Fisher Scientific Inc.
11.5. Bio-Rad Laboratories, Inc.
11.6. Becton, Dickinson and Company
11.7. Merck KGaA (MilliporeSigma)
11.8. bioMerieux SA
11.9. Lonza Group AG (Bioscience)
11.10. Cytiva (Danaher)
11.11. Agilent Technologies, Inc.
11.12. Sony Biotechnology Inc.
11.13. Nexcelom (Revvity)
11.14. SGS SA
11.15. Cellular Origins (Cell Therapy Analytics)
圖表清單 List of Tables & Figures
Table 1. Global Cell Therapy Quality Control Revenue Forecast by Test Type, 2026-2035 (US$ Mn)
Figure 1. Global Cell Therapy Quality Control Market Snapshot, 2026 & 2035
Table 2. Global Cell Therapy Quality Control Revenue Forecast by Product Type, 2026-2035 (US$ Mn)
Figure 2. Global Cell Therapy Quality Control Market Share by Product Type, 2026 & 2035
Table 3. Global Cell Therapy Quality Control Revenue Forecast by Technology, 2026-2035 (US$ Mn)
Figure 3. Release Testing Workflow and Turnaround Time for Autologous Cell Therapy Batches
Table 4. Global Cell Therapy Quality Control Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Rapid Microbiological Method Adoption Versus Compendial Sterility Testing
Table 5. North America Cell Therapy Quality Control Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Cell Therapy Quality Control Growth Opportunity Analysis
Table 6. Europe Cell Therapy Quality Control Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Potency Assay Development Requirements Across Clinical Phases
Table 7. Asia Pacific Cell Therapy Quality Control Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Cell Therapy Quality Control Market Participants
Table 8. Latin America and Middle East & Africa Cell Therapy Quality Control Revenue Forecast, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們